261 related articles for article (PubMed ID: 25305035)
1. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.
Markowitz J; Brooks TR; Duggan MC; Paul BK; Pan X; Wei L; Abrams Z; Luedke E; Lesinski GB; Mundy-Bosse B; Bekaii-Saab T; Carson WE
Cancer Immunol Immunother; 2015 Feb; 64(2):149-59. PubMed ID: 25305035
[TBL] [Abstract][Full Text] [Related]
2. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients.
Khaled YS; Ammori BJ; Elkord E
J Immunol Res; 2014; 2014():879897. PubMed ID: 24741628
[TBL] [Abstract][Full Text] [Related]
4. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
5. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
[TBL] [Abstract][Full Text] [Related]
7. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
Mundy-Bosse BL; Young GS; Bauer T; Binkley E; Bloomston M; Bill MA; Bekaii-Saab T; Carson WE; Lesinski GB
Cancer Immunol Immunother; 2011 Sep; 60(9):1269-79. PubMed ID: 21604071
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
[TBL] [Abstract][Full Text] [Related]
9. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
10. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.
Chen MF; Kuan FC; Yen TC; Lu MS; Lin PY; Chung YH; Chen WC; Lee KD
Oncotarget; 2014 Sep; 5(18):8716-28. PubMed ID: 25238263
[TBL] [Abstract][Full Text] [Related]
11. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.
Mace TA; Ameen Z; Collins A; Wojcik S; Mair M; Young GS; Fuchs JR; Eubank TD; Frankel WL; Bekaii-Saab T; Bloomston M; Lesinski GB
Cancer Res; 2013 May; 73(10):3007-18. PubMed ID: 23514705
[TBL] [Abstract][Full Text] [Related]
13. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
Gabitass RF; Annels NE; Stocken DD; Pandha HA; Middleton GW
Cancer Immunol Immunother; 2011 Oct; 60(10):1419-30. PubMed ID: 21644036
[TBL] [Abstract][Full Text] [Related]
14. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
15. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.
Goedegebuure P; Mitchem JB; Porembka MR; Tan MC; Belt BA; Wang-Gillam A; Gillanders WE; Hawkins WG; Linehan DC
Curr Cancer Drug Targets; 2011 Jul; 11(6):734-51. PubMed ID: 21599634
[TBL] [Abstract][Full Text] [Related]
19. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
Verschoor CP; Johnstone J; Millar J; Dorrington MG; Habibagahi M; Lelic A; Loeb M; Bramson JL; Bowdish DM
J Leukoc Biol; 2013 Apr; 93(4):633-7. PubMed ID: 23341539
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
